Press releases

Indivior Statement Regarding State Attorney General’s Recent Announcements Relating to SUBOXONE® (buprenorphine and naloxone) Film Settlements

Richmond, VA April 28, 2021- Indivior PLC (LON: INDV) - The various state settlement agreements being announced this week are administrative in nature, and simply formalize the individual state settlements which were previously agreed to in principle as part of the July 2020 criminal and civil resolution between Indivior and the states (and the federal government). As such, there is no new financial or legal obligation that has arisen. The Company was pleased to put those issues behind it in 2020 and remains focused on realizing its patient-focused Vision and fulfilling its compliance commitments.

The Company will have no further comment on this matter.

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting


Investor Contact:

Jason Thompson,
Indivior Vice President,
Investor Relations
+1 804-402-7123

Media Contacts:

Tulchan Communications
+44 207-353-4200

+1 804-594-0836